Screener
Palvella Therapeutics PVLA Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Palvella Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210463
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Long-term portion of operating lease liability | 375 | 431 |
| Royalty agreement liability | 19,799 | 17,760 |
| Derivative liabilities – royalty agreement | 2,157 | 2,041 |
| Total liabilities | 31,446 | 31,576 |
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity: | ||
| Common stock, $0.001 par value; 200,000,000 shares authorized; 14,313,659 and 12,380,933 shares issued and outstanding at March 31, 2026 and December 31, 2025 | 14 | 12 |
| Additional paid-in capital | 383,421 | 163,338 |
Item 1. Financial Statements.
FAQ
- What is Palvella Therapeutics's total liabilities?
- Palvella Therapeutics (PVLA) reported total liabilities of $31.45M in Q1 2026.
- How has Palvella Therapeutics's total liabilities changed year-over-year?
- Palvella Therapeutics's total liabilities increased by 31.8% year-over-year, from $23.86M to $31.45M.
- What is the long-term trend for Palvella Therapeutics's total liabilities?
- Over 5 years (2020 to 2025), Palvella Therapeutics's total liabilities has grown at a -15.7% compound annual growth rate (CAGR), from $73.98M to $31.58M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Palvella Therapeutics's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude